Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine

Phase 3 Completed 116 enrolled GlaxoSmithKline

RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals' (formerly, SmithKline Beecham Biologicals) reduced-antigen-content acellular pertussis vaccine and reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in comparison with Tedivax-Adult™/ Td-Rix™

Timeline

Start: 1997-10
Primary completion: 1998-12
Completion: 1998-12

Publications

Results Van Damme P, Burgess M. Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. Vaccine. 2004 Jan 2;22(3-4):305-8. doi: 10.1016/j.vaccine.2003.08.012.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Boostrix	Vaccine	—	Intramuscular
Subject	GSK Biologicals' reduced-antigen-content acellular pertussis vaccine	Vaccine	—	Intramuscular
Comparator	Tedivax-Adult™	Unknown	—	Intramuscular

Indications

No indication recorded.